Opexa Therapeutics reports plans for at-the-market common stock sale

Company engages agent Brinson Patrick Securities in Sept. 6 agreement

By Devika Patel

Knoxville, Tenn., Sept. 7 - Opexa Therapeutics, Inc. arranged an at-the-market issuance sales agreement for common stock with Brinson Patrick Securities Corp. on Sept. 6, according to an 8-K filed Friday with the Securities and Exchange Commission.

The agent will be paid a 3% fee.

The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.